SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report

RATIONALE: The ongoing coronavirus pandemic has caused severe acute respiratory syndrome, posing a significant challenge for patients receiving immunotherapy for immune-mediated inflammatory diseases. As of January 2022, immunosuppressants such as tumor necrosis factor inhibitors (anti-TNFα) and aza...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhalabi, Marouf, Eddin, Kamal Alaa, Ali, Fadwa, Abbas, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797526/
https://www.ncbi.nlm.nih.gov/pubmed/35089243
http://dx.doi.org/10.1097/MD.0000000000028722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797526/
https://www.ncbi.nlm.nih.gov/pubmed/35089243
http://dx.doi.org/10.1097/MD.0000000000028722

Ejemplares similares